The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a rural region known for high rates of that disease among infants ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
The researchers found that 45,693 outpatient visits, 15,866 emergency department visits, and 7571 hospitalizations among infants would be prevented each year by year-round maternal vaccination.
Seasonal maternal RSV vaccination may be cost-effective, particularly for those with higher risks. HealthDay News — Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab ...
Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it.
Nirsevimab has been hailed by Sanofi chief executive Paul Hudson as one of the brightest prospects in the company's pipeline, providing a brand new way to tackle RSV, which according to the World ...